Stephan Hjorth

Affiliations: 
Integrative Pharmacology, AstraZeneca R&D, Molndal, Sweden 
Area:
CNS, appetite, serotonin, cannabinoid, in vivo
Google:
"Stephan Hjorth"
Mean distance: 17.32 (cluster 6)
 
SNBCP
Cross-listing: Chemistry Tree

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Skowronski AA, Morabito MV, Mueller BR, et al. (2014) Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese mice. Obesity (Silver Spring, Md.). 22: 1287-95
Wennerberg M, Cheng L, Hjorth S, et al. (2011) Binding properties of antagonists to cannabinoid receptors in intact cells. Fundamental & Clinical Pharmacology. 25: 200-10
Boström J, Olsson RI, Tholander J, et al. (2010) Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20: 479-82
Lindström E, Ravnefjord A, Brusberg M, et al. (2009) The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats. The Journal of Pharmacology and Experimental Therapeutics. 329: 1048-55
Ryberg E, Larsson N, Sjögren S, et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology. 152: 1092-101
Ryberg E, Vu HK, Larsson N, et al. (2005) Identification and characterisation of a novel splice variant of the human CB1 receptor. Febs Letters. 579: 259-64
Bohlooly-Y M, Mahlapuu M, Andersén H, et al. (2004) Osteoporosis in MCHR1-deficient mice. Biochemical and Biophysical Research Communications. 318: 964-9
Felton TM, Kang TB, Hjorth S, et al. (2003) Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn-Schmiedeberg's Archives of Pharmacology. 367: 297-305
Wikell C, Apelqvist G, Hjorth S, et al. (2002) Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 12: 327-36
Wikell C, Kugelberg FC, Hjorth S, et al. (2001) Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy. Clinical Neuropharmacology. 24: 324-33
See more...